| Health / Medical Topics |
ALVAC(2) Melanoma Multi-antigen Vaccine
A therapeutic cancer vaccine, based on a replication-defective recombinant canarypox virus (ALVAC) encoding multiple melanoma antigens, with potential immunostimulatory and antineoplastic activities. Vaccination with ALVAC(2) melanoma multi-antigen therapeutic vaccine may stimulate the host immune system to mount an immune response against antigen-expressing melanoma cells, resulting in inhibition of tumor growth and/or metastasis. (NCI Thesaurus)
YOU MAY ALSO LIKE
A cancer vaccine containing a replication-defective recombinant canarypox virus (ALVAC), encoding an epitope of MART-1 (melanoma antigen recognized by T-cells), with potential…
A vaccine comprise of a canarypox viral vector that carries the gene for human B7.1 (CD80 antigen) with potential use as an…
A cancer vaccine consisting of a replication-defective recombinant canarypox virus (ALVAC) encoding the cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic…
A cancer vaccine made with a form of the canarypox virus that does not cause disease in people. It is being studied…
A cancer vaccine that uses a viral vector system derived from the canarypox virus engineered to target the carcinoembryonic antigen (CEA). It…
A replication-defective recombinant canarypox virus (ALVAC) that contains the entire human carcinoembryonic antigen (CEA) gene. Vaccination with ALVAC-CEA (VCP248) may stimulate…
